Charles S. Fuchs, MD, MPH
Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new Director and Physician-in-Chief at Smilow Cancer Hospital at Yale New Haven, effective January 1, 2017.
Dr. Fuchs will be taking the reins of the Smilow Cancer Hospital, a 14-story, 500,000-square-foot facility that includes 168 private inpatient rooms, multidisciplinary outpatient treatment centers, 12 operating rooms, infusion suites, diagnostic imaging services, and specialized women’s and children’s services; and Yale Cancer Center, a collaboration between scientists and physicians at Yale School of Medicine and Smilow Cancer Hospital.
An expert in gastrointestinal cancers and cancer epidemiology, Dr. Fuchs is currently Professor of Medicine at Harvard Medical School and Chief of the Gastrointestinal Oncology Division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.
Dr. Fuchs has spearheaded clinical trials that have resulted in U.S. Food and Drug Administration approval of several new drugs. He plans to continue to expand clinical trials and science at Yale Cancer Center and will seek to align these efforts with discoveries that emerge across Yale’s research enterprise. His vision is to advance Yale’s capacity to do innovative clinical, translational, population, and basic research to further enhance Yale’s position as a leader in cancer prevention, biology, and treatment.
“The Cancer Center and Smilow have had impressive growth over the past 5 years,” said Dr. Fuchs. “I’m excited about the opportunity to continue to expand the breadth and depth of the clinical practice, as well as the extraordinary cancer research ongoing at Yale, to meaningfully improve the outcome of patients.”
Dr. Fuchs received his medical degree from Harvard Medical School and his MPH from Harvard School of Public Health. He completed his medical residency at Brigham and Women’s Hospital, where he also served as Chief Medical Resident, and his medical oncology fellowship at Dana-Farber Cancer Institute. Most recently, he served as a member of the National Cancer Institute Blue Ribbon Panel Working Group. ■
